This page shows the latest sarcoma news and features for those working in and with pharma, biotech and healthcare.
This includes studies, either underway or planned, in small cell lung cancer, breast cancer, colorectal cancer, gastric cancer, triple-negative breast cancer, sarcoma, melanoma, renal cell carcinoma, bladder cancer and
He is also specialist in lung cancer and sarcoma, and climbed up the centre’s professional ladder since joining in 2015.
breast, lung, sarcoma, gastric, bladder, endometrial, ovarian and oesophageal cancers.
Authorisation revoked for Lartruvo. Friday’s ruling was also notable for the CHMP’s decision to revoke the marketing authorisation for Eli Lilly’s sarcoma treatment Lartruvo, after the drug failed
Existing patients can use access programme. Eli Lilly is to withdraw its soft tissue sarcoma treatment Lartruvo from the market after it failed a post-marketing efficacy study. ... Advanced soft tissue sarcoma is a rare and difficult-to-treat cancer.
as well as an independent assessment of the clinical benefit/risk ratio for NBTXR3 in a phase 3 programme in soft tissue sarcoma (STS).
More from news
Approximately 5 fully matching, plus 47 partially matching documents found.
Among the noteworthy approvals are Lartruvo (for the treatment of soft tissue sarcoma, approved in the EU and US), Rubraca (for the treatment of ovarian cancer, only approved in the US),
The Practical Guide was launched as part of a Takeda sponsored symposium at the British Sarcoma Group’s annual conference.
Also, this month Merck &Co has handed back the rights to Ariad Pharmaceutical's ridaforolimus, a mTOR inhibitor in a phase III trial for advanced sarcoma.
And that was absolutely correct.”. After selling off investigational sarcoma treatment ridaforolimus to Merck &Co following an aborted collaboration attempt, ponatinib emerged as the front-runner in the company's pipeline
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Videos such as this one from the Sarcoma UK Clinical Trials Hub explain how trials work, answer typical questions and present the benefits to possible participants.
2. Characterised by very low levels of CD4+ T cells, and the presence of AIDS-related pathologies (such as tuberculosis and Kaposi’s sarcoma), the diagnosis of AIDS marks just how
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...